Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gogoro Inc (GGR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Gogoro IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Gogoro Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gogoro Inc trades at $2.51 (market cap $52.19M), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2572.3× Gogoro Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.

GGRVRTX
Market Cap
$52.19M$134.25B
Sector
TechnologyHealth
52-Week High
$7.50$529.65
52-Week Low
$2.55$376.62
Enterprise Value
$354.63M$128.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gogoro Inc

GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).

The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $525.72, up 0.35% on the day, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales guidance, driven by cystic fibrosis drug strength and new product contributions. Profitability remains robust with a 35% net income margin, though the P/E ratio of 30.85 reflects premium valuation.

Outlook is positive with 84% analyst buy ratings and a $534.25 consensus target, but risks include earnings volatility and competitive pressures. Upside hinges on execution of new launches and sustained CF franchise growth, while any clinical or regulatory setbacks could pressure the stock.

Returns comparison

Trailing returns across standard periods

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

Read more on GGR

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX